Logo

BNBX

BNB Plus Corp.

BNBX

BNB Plus Corp. • NASDAQ
$2.60 ▲ 4.42% (+0.11)
Market Cap $3.36 M
52w High $187.50
52w Low $2.13
Dividend Yield 0%
P/E -0.05
Volume 17.48K
Outstanding Shares 1.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $304.393K ▼ $3.699M ▼ $-3.945M ▼ -1.296K% ▼ $-34 ▲ $-3.616M ▼
Q2-2025 $983.374K ▼ $3.833M ▲ $-3.304M ▼ -336.004% ▼ $-230.25 ▲ $-3.343M ▼
Q1-2025 $1.197M ▲ $3.648M ▲ $-2.639M ▲ -220.573% ▲ $-420 ▼ $-2.905M ▲
Q4-2024 $813.107K ▲ $3.516M ▼ $-3.297M ▼ -405.45% ▼ $0 ▼ $-3.194M ▲
Q3-2024 $472.789K $3.549M $1.88M 397.597% $1.17K $-3.306M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.728M ▼ $9.935M ▼ $2.947M ▲ $7.263M ▼
Q2-2025 $6.823M ▼ $13.036M ▼ $2.811M ▼ $10.46M ▼
Q1-2025 $9.294M ▲ $15.971M ▲ $3.421M ▼ $12.753M ▲
Q4-2024 $6.431M ▼ $12.789M ▼ $3.821M ▼ $9.143M ▼
Q3-2024 $10.442M $16.69M $4.456M $12.392M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.581M ▼ $-2.816M ▲ $10.077K ▲ $723.056K ▼ $-2.083M ▲ $-2.827M ▲
Q2-2025 $-3.336M ▼ $-3.185M ▲ $-185.319K ▼ $899.249K ▼ $-2.471M ▼ $-3.37M ▲
Q1-2025 $-2.669M ▲ $-3.326M ▼ $-116.879K ▲ $6.306M ▲ $2.863M ▲ $-3.443M ▲
Q4-2024 $-3.314M ▼ $-3.249M ▲ $-371.25K ▼ $-390.721K ▼ $-4.011M ▼ $-3.62M ▼
Q3-2024 $2.122M $-3.495M $-21.826K $10.809M $7.292M $-3.516M

Five-Year Company Overview

Income Statement

Income Statement BNBX looks like an early‑stage, largely pre‑revenue company. Sales have been minimal for several years, and the business has consistently run at an operating loss. That means the company is still in the stage of spending significantly more on salaries, R&D, and overhead than it brings in from customers. The large negative earnings per share figures mainly reflect this small revenue base and repeated losses spread over a modest equity structure, rather than any sudden collapse in a big, mature business. Overall, the income statement tells the story of a company still trying to turn promising technology into a commercially meaningful business.

Balance Sheet

Balance Sheet The balance sheet is very light: only a small pool of assets, almost all of which is cash, and no meaningful debt. That simplifies the capital structure but also highlights how limited the financial cushion is. Equity is positive but thin, suggesting the company does not have a large buffer to absorb continued losses without raising new capital. In practice, this profile is typical of a small, development‑stage biotech, but it also means sensitivity to any setbacks in funding or execution is high.

Cash Flow

Cash Flow There is no detailed cash flow data provided, but the pattern of small revenues and steady losses strongly implies ongoing cash burn from operations. With no significant property or equipment base, capital spending is likely modest, but the company still needs to fund R&D, staff, and overhead. Given the small asset and equity base, BNBX probably depends on periodic equity raises or other external funding to keep going. Without clear visibility into future funding sources, cash runway and dilution risk are key uncertainties.

Competitive Edge

Competitive Edge In its original form, the company carved out a niche in enzymatic DNA synthesis and DNA-based supply chain security. Its LineaDNA and CertainT platforms, along with specialized diagnostic offerings, give it some technological distinctiveness and intellectual property. It operates, however, in a competitive field with much larger, better‑funded peers in synthetic biology and diagnostics. Its moat comes from know‑how, patents, and early work in specific applications, but scale, brand recognition, and commercial reach are limited. The recent pivot toward a digital‑asset treasury strategy also blurs its identity, making it less clear how it will be positioned versus pure biotech peers or pure crypto‑related entities.

Innovation and R&D

Innovation and R&D On the innovation side, BNBX has genuine scientific strengths: enzymatic DNA synthesis (LineaDNA), mRNA template production (LineaIVT), donor DNA for gene editing, and DNA tagging for supply chains. These are forward‑looking fields with meaningful potential if adoption grows and partnerships materialize. The company has also developed a pharmacogenomic test in diagnostics, pointing to ongoing R&D activity and regulatory engagement. The new digital‑asset treasury strategy is not R&D in the traditional sense; it is more of a financial experiment layered on top of a small biotech platform. That creates both optionality and distraction risk: management attention and capital will need to be split between building out advanced biology capabilities and navigating a highly volatile crypto environment.

Summary

BNBX is a very small, loss‑making company with advanced but early‑stage technologies and a thin financial base. Its historical numbers look like those of a development‑stage biotech: minimal revenue, recurring losses, and reliance on cash reserves and future external funding. On the positive side, it has differentiated scientific platforms with potential applications in therapeutics, diagnostics, and supply chain security. On the risk side, commercial traction is still limited, competition is intense, and the balance sheet does not offer much cushion. The recent move into a BNB‑focused digital‑asset treasury strategy adds a layer of complexity and uncertainty, mixing a high‑risk financial strategy with a capital‑intensive biotech model. Future outcomes will depend heavily on execution in both arenas: turning its scientific assets into durable revenue streams while managing funding needs and the volatility introduced by its crypto‑related activities.

NEWS

November 17, 2025 · 8:00 AM UTC

Applied DNA Rebrands as BNB Plus Corp., Elects Josh Kruger as Chairman of the Board

Read more

October 28, 2025 · 8:00 AM UTC

BNBX Launches Digital Asset Treasury Dashboard and Provides Corporate Update

Read more

October 22, 2025 · 8:00 AM UTC

Applied DNA Sciences Closes up to $58 Million Private Placement; Announces Initial BNB Holdings Valued at Over $17 Million

Read more

October 6, 2025 · 8:00 AM UTC

Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy

Read more